FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.973,02 +197,64 (+0,52%) Nasdaq
15.352,86 -248,64 (-1,59%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,21 +0,48 (+0,58%) Bitcoin EUR
60.500,24 +1.863,34 (+3,18%)
Ocugen, Inc. (OCGN)
| Chiusura precedente | 1,3200 |
| Aperto | 1,2900 |
| Denaro | 1,3000 x 300 |
| Lettera | 1,3100 x 100 |
| Min-Max giorno | 1,2700 - 1,3700 |
| Intervallo di 52 settimane | 0,3450 - 2,1050 |
| Volume | |
| Media Volume | 8.971.411 |
| Capitalizzazione | 337,096M |
| Beta (5 anni mensile) | 3,74 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2600 |
| Prossima data utili | 03 mag 2024 - 07 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,33 |
GlobeNewswireOcugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms and delivery routesOCU500 will be tested as both inhaled and intranasal vaccine candidates Clinical trials scheduled to start in early 2024 MALVERN, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies
- GlobeNewswire
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort. Dr. Musunuri will provid
- GlobeNewswire
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 i
